Search | HMA-EMA Catalogues of real-world data sources and studies

Identify the determinants associated with antibiotic prescription in teleconsultation using the French National Health Data System (TELEPRESAGE)

France

EU PAS number:

EUPAS1000000532

First published:

07/08/2026

Last updated 07/08/2026

Study Finalised

DARWIN EU® – Benzodiazepine use during pregnancy: a descriptive study characterising exposure, pregnancy loss, and covariates to inform future safety studies

Norway

Spain

EU PAS number:

EUPAS1000000536

First published:

02/04/2025

Last updated 07/08/2026

Study Ongoing

Evaluation of the Effectiveness of Implementation of Additional Risk Minimization Measures (aRMM) Materials for Xeljanz® (Tofacitinib) / Rheumatoid Arthritis (RA) indication in Nigeria via a Survey among Prescribers: A Non-Interventional Post Authorization Safety Study (PASS).

Nigeria

EU PAS number:

EUPAS1000000900

First published:

27/05/2026

Last updated 07/08/2026

Study Planned

Effectiveness and Safety of Avacopan as Add-on to Standard of Care (SOC) Versus SOC Alone in ANCA-associated Vasculitis (LIBRA) (20240051)

United States

EU PAS number:

EUPAS1000000985

First published:

08/05/2026

Last updated 07/08/2026

Study Ongoing

A Rapid Surveillance and Cohort Post-Marketing Safety Study to Evaluate the Safety of Respiratory Syncytial Virus Vaccine (ABRYSVO™) Exposure During Pregnancy in the United States (C3671027)

United States

EU PAS number:

EUPAS1000000115

First published:

02/05/2024

Last updated 07/08/2026

Study Ongoing

Vedolizumab-4024: A Multi-center, Longitudinal, Observational Study of the Effectiveness of Vedolizumab on Clinical Outcomes and Health-Related Quality if Life in Biologic Naive Patients with Inflammatory Bowel Diseases in Serbia Over a 2-year Period

Montenegro

Serbia

EU PAS number:

EUPAS32913

First published:

28/01/2020

Last updated 07/08/2026

Study Finalised

DARWIN EU® Use of take-home naloxone for opioid overdose treatment

Belgium

Germany

Spain

United Kingdom

EU PAS number:

EUPAS105644

First published:

11/07/2023

Last updated 07/08/2026

Study Finalised

DARWIN EU® - Characterisation of exposure to acitretin and purpura and related conditions

Denmark

Netherlands

Spain

United Kingdom

EU PAS number:

EUPAS1000000429

First published:

04/01/2025

Last updated 07/08/2026

Study Ongoing

DARWIN EU® - Antipsychotic prescribing in people with dementia in Europe: a descriptive analysis of trends and patient characteristics

Belgium

Croatia

Denmark

Germany

Netherlands

Spain

EU PAS number:

EUPAS1000000382

First published:

09/12/2024

Last updated 07/08/2026

Study Finalised

DARWIN EU® - Antipsychotic prescribing in the general population in Europe: a descriptive analysis of trends and patient characteristics

Belgium

Croatia

Denmark

Germany

Netherlands

Spain

EU PAS number:

EUPAS1000000330

First published:

04/10/2024

Last updated 07/08/2026

Study Finalised

DARWIN EU® - Antipsychotic prescribing in children in Europe: a descriptive analysis of trends and patient characteristics

Croatia

Denmark

Germany

Netherlands

Norway

Spain

EU PAS number:

EUPAS1000000592

First published:

22/05/2025

Last updated 07/08/2026

Study Finalised

DARWIN EU® Age specific incidence rates of RSV related disease in Europe

Estonia

France

Germany

Spain

United Kingdom

EU PAS number:

EUPAS107708

First published:

28/11/2023

Last updated 07/08/2026

Study Finalised

Periodic Knowledge Assessment Survey of Healthcare Providers (HCPs) to Assess Understanding of the Risks with the Prolia® Risk Evaluation and Mitigation Strategy (REMS)

United States

EU PAS number:

EUPAS1000000393

First published:

12/12/2024

Last updated 06/08/2026

Study Ongoing

Risk of 4 obesity-related cancers after GLP-1 receptor agonist use

United States

EU PAS number:

EUPAS1000000990

First published:

30/04/2026

Last updated 06/08/2026

Study Ongoing

Fezolinetant Experience for the Treatment of Vasomotor Symptoms Associated with Menopause Among Women in a German Real-life Setting

Germany

EU PAS number:

EUPAS1000000132

First published:

26/09/2024

Last updated 06/08/2026

Study Ongoing

An Active Surveillance, Post Authorization Safety Study (PASS) to Investigate Relevant Safety Outcomes among Patients Treated with Flixabi for Rheumatoid Arthritis (RA) within the German Registry Rheumatoide Arthritis: Beobachtung der Biologika-Therapie (RABBIT)

Germany

EU PAS number:

EUPAS1000001076

First published:

06/08/2026

Last updated 06/08/2026

Study Finalised

Remibrutinib in real-world clinical practice: a prospective, multi-country, non-interventional, effectiveness and safety study (REASSERT) - Local adaptation in Germany from global umbrella protocol (CLOU064A2402)

Germany

EU PAS number:

EUPAS1000001003

First published:

29/05/2026

Last updated 06/08/2026

Study Ongoing

Sustainability of response to biologics in severe asthma and predictors of late failure among patients in an international registry (SHINE)

Argentina

Belgium

Brazil

Bulgaria

Canada

Colombia

Denmark

Estonia

Greece

Ireland

Italy

Japan

Korea, Republic of

Kuwait

Mexico

Norway

Poland

Portugal

Saudi Arabia

Singapore

Spain

Taiwan

United Arab Emirates

United Kingdom

United States

EU PAS number:

EUPAS1000000788

First published:

23/10/2025

Last updated 06/08/2026

Study Finalised

Real World Outcomes of Patients Treated with Vericiguat in German Routine Care (ROVER)

Germany

EU PAS number:

EUPAS1000000221

First published:

05/07/2024

Last updated 06/08/2026

Study Finalised

Registry of Asthma Patients Initiating DUPIXENT® (RAPID)

Canada

Denmark

France

Italy

Japan

Puerto Rico

Spain

Sweden

United Kingdom

United States

EU PAS number:

EUPAS41963

First published:

18/10/2021

Last updated 06/08/2026

Study Ongoing

DARWIN EU® - Sex differences in treatment patterns for venous thromboembolic events in European countries

Denmark

Finland

Netherlands

Spain

United Kingdom

EU PAS number:

EUPAS1000001079

First published:

06/08/2026

Last updated 06/08/2026

Study Ongoing

DARWIN EU® - Alzheimer’s Disease: Incidence, Prevalence, and Individuals' Characteristics

Croatia

Denmark

Germany

Netherlands

United Kingdom

EU PAS number:

EUPAS1000000826

First published:

10/11/2025

Last updated 06/08/2026

Study Finalised

Haematological Malignancy Research Network

United Kingdom

First published:

02/07/2025

Last updated 04/08/2026

Data source

Human

Cancer registry

Record completeness: 49%

Compare Compare

AP-HM IATROS

France

First published:

01/02/2024

Last updated 04/08/2026

Data source

Human

Hospital inpatient records Hospital outpatient visit records Other

Record completeness: 84%

Compare Compare

Tumour Lysis Syndrome Associated with Lenvatinib: an Investigator-Initiated, Retrospective Observational Post-Authorisation Safety Study (TELSTAR)

Portugal

EU PAS number:

EUPAS1000000977

First published:

13/04/2026

Last updated 04/08/2026

Study Finalised

A retrospective matched cohort study on the association between herpes zoster vaccination and dementia and mild cognitive impairment using electronic health records (ZOSTER-122 AIML 222419)

United States

EU PAS number:

EUPAS107206

First published:

24/10/2023

Last updated 04/08/2026

Study Finalised

Elafibranor Pregnancy Surveillance Program: A Study to Evaluate the Safety of Elafibranor During Pregnancy

European Union

United Kingdom

United States

EU PAS number:

EUPAS1000000891

First published:

23/04/2026

Last updated 04/08/2026

Study Ongoing

Registry to Document Treatment Effectiveness, Safety, Including Prospective Long-term Outcomes in Participants with Progressive Familial Intrahepatic Cholestasis (PFIC) who take Odevixibat (Bylvay)

China

EU PAS number:

EUPAS1000000975

First published:

11/05/2026

Last updated 04/08/2026

Study Ongoing

Prospective Non-Interventional Study Evaluating the Long-term Safety of Odevixibat in Patients With Alagille Syndrome (ALGS)

European Union

EU PAS number:

EUPAS1000000961

First published:

08/05/2026

Last updated 04/08/2026

Study Ongoing

Concept Elicitation Qualitative Study: Migraine Patient Experiences with Zavegepant

United States

EU PAS number:

EUPAS1000000442

First published:

04/04/2025

Last updated 04/08/2026

Study Finalised

A prospective, multicenter, observational, post-authorization safety study (PASS) to evaluate the long term safety profile of LEMTRADA® (alemtuzumab) treatment in patients with relapsing forms of multiple sclerosis (RMS) (GZ402673-OBS13434)

Australia

Austria

Belgium

Bulgaria

Canada

Cyprus

Czechia

Denmark

Estonia

Finland

Germany

Greece

Hungary

Ireland

Israel

Italy

Lithuania

Mexico

Netherlands

Norway

Poland

Slovakia

Slovenia

Spain

Sweden

Switzerland

United Kingdom

United States

EU PAS number:

EUPAS7346

First published:

24/09/2014

Last updated 04/08/2026

Study Ongoing

VAC4EU Postauthorisation Effectiveness Study of BIMERVAX® Vaccine in Europe

Spain

EU PAS number:

EUPAS1000000337

First published:

21/10/2024

Last updated 04/08/2026

Study Planned

VAC4EU Postauthorisation Safety Study of BIMERVAX® Vaccine in Europe

Spain

EU PAS number:

EUPAS1000000321

First published:

21/10/2024

Last updated 04/08/2026

Study Planned

Real-World Characteristics and Treatment Patterns of Patients Treated with Talazoparib + Enzalutamide for Metastatic Castration- Resistant Prostate Cancer in the US Community Oncology Setting

United States

EU PAS number:

EUPAS1000000931

First published:

04/08/2026

Last updated 04/08/2026

Study Planned

French National Registry of Rare Diseases (Banque Nationale de Données Maladies Rares)

France

First published:

28/09/2022

Last updated 31/07/2026

Data source

Human

Disease registry Other

Record completeness: 93%

Compare Compare

PASS TachoSil Evaluation (PasTel): Short- and long-term safety evaluation of TachoSil in paediatric population

Poland

EU PAS number:

EUPAS1000000505

First published:

28/04/2025

Last updated 31/07/2026

Study Ongoing

213825-Non-interventional (observational) post-licensure study to assess the vaccine effectiveness and safety of recombinant zoster vaccine (RZV) in the rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) patient populations in adults 18 years of age and older (EPI-ZOSTER-044 VE US)

United States

EU PAS number:

EUPAS48157

First published:

21/07/2022

Last updated 31/07/2026

Study Finalised

Cohort Study to Evaluate Fetal and Infant Outcomes Following Maternal Exposure to Bimekizumab during Pregnancy

United States

EU PAS number:

EUPAS1000001042

First published:

31/07/2026

Last updated 31/07/2026

Study Planned

Assessment of the Association of Progression to High-Risk Varices With Death and Liver Transplantation Rates in Patients With Compensated Cirrhosis

Sweden

EU PAS number:

EUPAS1000001061

First published:

30/07/2026

Last updated 30/07/2026

Study Ongoing

Prospective Non-interventional Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment (CABOCARE)

Austria

Germany

EU PAS number:

EUPAS108004

First published:

11/01/2024

Last updated 30/07/2026

Study Ongoing

Search all content

Results(4718)